[Abstract Only] Randomized Trial: Monoclonal Antibody for Patients with Severe Chronic Rhinosinusitis with Nasal Polyps
2 Oct, 2019 | 22:17h | UTCEfficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials – The Lancet (link to abstract – $ for full-text)
Related Commentary on Twitter
NEW Research—Efficacy & safety of dupilumab in patients w/ severe chronic #rhinosinusitis w/ #nasalpolyps (LIBERTY NP SINUS-24 & LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials https://t.co/YH5khPeHxz pic.twitter.com/PR12UBV6Kf
— The Lancet (@TheLancet) September 20, 2019